Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

946 ARTÍCULOS , VIENDO DEL 826 AL 840

Examining the role of antioxidant supplementation in mitigating oxidative stress markers in Alzheimer's disease: a comprehensive review

Jawad M, Uthirapathy S, Altalbawy FMA, Oghenemaro EF, Rizaev J, Lal M, Eldesoqui M, Sharma N, Pramanik A, Al-Hamairy AK.

Inflammopharmacology. 2025 Feb;33(2):573-592. doi: 10.1007/s10787-024-01622-9. Epub 2024 Dec 19.

Critical nodes in precision diagnosis and treatment of Alzheimer's disease: exploration of multidimensional biomarkers and prospects for targeted intervention

Zuo Y, Ding X, Sun Y, Wang L, Song Y, Zhao Z, Liu C.

J Neurol Sci. 2025 Dec 15;479:123734. doi: 10.1016/j.jns.2025.123734. Epub 2025 Oct 28.

The neuroinflammatory role of microRNAs in Alzheimer's disease: pathological insights to therapeutic potential

Liu W, Rao X, Sun W, Chen X, Yu L, Zhang J, Chen J, Zheng X.

Mol Cell Biochem. 2025 May;480(5):2689-2706. doi: 10.1007/s11010-024-05164-0. Epub 2024 Nov 20.

Integrating artificial intelligence with small molecule therapeutics and precision medicine for neurochemical understanding of Alzheimer's diseases

Alshehri ZS.

Neuroscience. 2025 Nov 1;586:44-57. doi: 10.1016/j.neuroscience.2025.08.055. Epub 2025 Sep 18.

Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's Disease

Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, Paul J, Tolar M.

Clin Pharmacokinet. 2025 Mar;64(3):407-424. doi: 10.1007/s40262-025-01482-8. Epub 2025 Feb 5.

Precision exercise in older adults with early Alzheimer's disease: The study protocol of the FIT-AD Sequential, Multiple Assignment, Randomized Trial (SMART)

Yu F, Todd M, Salisbury D, Maxfield M, Pruzin J, Joseph RP, Su Y, Li D, Baena E, Coon D.

Trials. 2025 Oct 15;26(1):416. doi: 10.1186/s13063-025-09040-0.

Association of dipeptidyl peptidase-4 with Alzheimer's disease: A new therapeutic prospect

Wang X, Chen L, Li W, He Z, Jiang H.

J Alzheimers Dis. 2025 Jan;103(2):319-332. doi: 10.1177/13872877241304673. Epub 2025 Jan 8.

Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer's Treatment

Fatima R, Khan Y, Maqbool M, Ramalingam PS, Khan MG, Bisht AS, Hussain MS.

Curr Protein Pept Sci. 2025;26(7):515-545. doi: 10.2174/0113892037362037250205143911.

Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies

La Joie R, Cummings JL, Dage JL, Galasko D, Ikonomovic MD, Karikari TK, Landau SM, Llibre-Guerra JJ, Mummery CJ, Ossenkoppele R, Price JC, Risacher SL, Smith R, van Dyck CH, Carrillo MC.

Alzheimers Dement. 2025 Nov;21(11):e70997. doi: 10.1002/alz.70997.

Is the Era of One-Size-Fits-All Alzheimer's Treatment Officially Over?

Verma S, Kumari K, Kesharwani P, Verma K, Dwivedi J, Paliwal S, Sharma S.

J Mol Neurosci. 2025 Dec 22;76(1):3. doi: 10.1007/s12031-025-02445-1.

Diverse role of S100 calcium-binding protein B in alzheimer's disease: pathological mechanisms and therapeutic implications

Sarkar S, Porel P, Kosey S, Aran KR.

Inflammopharmacology. 2025 Apr;33(4):1803-1816. doi: 10.1007/s10787-025-01697-y. Epub 2025 Mar 9.

Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease

Grill JD, Tam S, Thai G, Vides B, Pierce AL, Green K, Gillen DL, Teng E, Kremen S, Beigi M, Rissman RA, Léger GC, Balasubramanian A, Revta C, Morrison R, Jennings R, Pa J, Zhang J, Jin S, Messer K, Feldman HH.

Neurology. 2025 Jan 14;104(1):e210152. doi: 10.1212/WNL.0000000000210152. Epub 2024 Dec 13.

Towards a better diagnosis and treatment of dementia: Identifying common and distinct neuropathological mechanisms in Alzheimer's and vascular dementia

Vollhardt A, Frölich L, Stockbauer AC, Danek A, Schmitz C, Wahl AS.

Neurobiol Dis. 2025 May;208:106845. doi: 10.1016/j.nbd.2025.106845. Epub 2025 Feb 24.

A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD

Erichsen JM, Register TC, Sutphen C, Ma D, Gaussoin SA, Rudolph M, Rundle M, Bateman JT, Lockhart SN, Sai KKS, Whitlow C, Craft S.

Alzheimers Dement. 2025 Oct;21(10):e70704. doi: 10.1002/alz.70704.

Unraveling the Role of Autotaxin and Lysophosphatidic Acid in Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Potential

García-de Soto J, Castro-Mosquera M, Pouso-Diz JM, Fernández-Cabrera A, Rodríguez-Arrizabalaga M, Debasa-Mouce M, Camino-Castiñeiras J, Minguillón Pereiro AM, Aramburu-Núñez M, Romaus-Sanjurjo D, Aldrey JM, Pego-Reigosa R, Pías-Peleteiro JM, Sobrino T, Ouro A.

Int J Mol Sci. 2025 Jul 23;26(15):7068. doi: 10.3390/ijms26157068.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias